Entrada Therapeutics, Inc. (TRDA) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
Entrada Therapeutics, Inc. (TRDA)
A forensic read on Entrada Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
4.2
Altman Z-score
Clean
Earnings quality
3
Forensic signals
-51.2%
ROE
$300M
Market cap
Entrada Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 4.2, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-48%Return on invested capital.Return on invested capital is -48% and slipping from -42% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+10.7%/yrShare-count dilution.Diluted share count changed +32% over the last 3 years to FY2025 (+10.7%/yr). The count is GROWING — existing holders are being diluted. That's ~10.7% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~32%.
77% of revStock-based comp load.Stock-based compensation ran 77% of revenue in FY2025 — about $0.47 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-565.5%
Free Cash Flow$-129.6M
Latest Revenue$25.4M
Return on Equity-47.0%
Revenue Growth YoY-87.9%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Entrada Therapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about TRDA's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown